Opinions
The Panic-Proof Portfolio (Stockchase Research)
Simulations Plus, Inc.
SLP-Q
PAST TOP PICK
Sep 21, 2021
(A Top Pick Apr 13/21, Down 32%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with SLP has triggered its stop at $40. We recommend covering the remaining position at this time. We will look for better opportunities.
$40.480
Stock price when the opinion was issued
biotechnology
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
TOP PICK
Stockchase Research Editor: Michael O'Reilly SLP is a $1.2 billion healthcare software company that provides modeling and simulation products to drug companies and biotechs and other sectors. Recently reported revenues were up 27% on the year and net income rose 49%. Their recurring revenue model helps produce 78% gross margins and it carries minimal long term debt. It pays a small dividend, backed by a 45% payout ratio. We would buy this with a stop loss at $40, looking to achieve $83 -- upside potential over 40%. Yield 0.38% (Analysts’ price target is $82.50)
biotechnology
Advertising